OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT II trial - Diener, HC; Dodick, DW; Aurora, SK; Turkel, CC; DeGryse, RE; Lipton, RB (Cephalalgia, 2010)
et al.